Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Open-Label, Multicenter Study of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

NCT07104565 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT07104565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07104565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Open-Label, Multicenter Study of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Recruiting
Start date
December 29, 2025
Completion date
March 9, 2028
Enrollment
56 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia